Finland· FI-REL-REL54892

Givlaari

A givosiran product containing givosiran sodium, registered in Finland by Alnylam Netherlands B.V.. The same ATC class is registered in 14 of our 19 countries.

ATC A16AX16

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedGivlaariATCA16AX16REGISTER NO.FI-REL-REL54892PACKS LISTED0CHECKEDSeptember 27, 2026

Where it is registered

Givosiran is registered in 14 of 19 countries.

Countries holding a registration under ATC A16AX16 (givosiran), each read from that country’s own register.

  • This record: Finland, from Fimea (Finland)
  • 9 of them publish a price we can compare per daily dose

Givosiran · ATC A16AX16

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Polandprice
  • Spainprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Fimea (Finland)
Active substance
Givosiran sodium
Manufacturer
Alnylam Netherlands B.V.
Country
Finland (FI)
ATC code
A16AX16
ATC class
Givosiran
Defined daily dose
5.8 mg, P
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

105 interactions on record for givosiran.

Graded by severity as the source publishes them — 24 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Givosiran · interactions on record

105 records

  • 24 severe
  • 81 moderate

Most severe, free to view

  • EliglustatA16AX10severe
  • TemsirolimusL01EG01severe
  • EverolimusL01EG02severe
  • SirolimusL01EG04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/227f1f29-e18b-4a08-af3f-37ddd776ca79
GET /v1/drugs/227f1f29-e18b-4a08-af3f-37ddd776ca79?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": null,
  "form": "injektioneste, liuos",
  "route": "Ihon alle",
  "ddd_unit": null,
  "strength": "189 mg/ml",
  "atc_label": "givosiraani",
  "ma_number": null,
  "auth_status": "Myyntilupa myönnetty",
  "eu_ma_number": "EU/1/20/1428/001",
  "fimea_rel_id": "REL54892",
  "authorised_at": "2020-03-02"
}

See everything about givosiran.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.